|
Post by mango on Jan 7, 2018 21:42:17 GMT -5
I reviewed some of Liquidia's patents to get a better understanding of their technology...meh
GSK has inferior DPIs. To be honest—they suck.
|
|
|
Post by kc on Jan 7, 2018 23:51:57 GMT -5
Hillard just posted this link on Twitter. It’s from the NIH but I am not sure that it has any connection to MannKind.
|
|
|
Post by mnholdem on Jan 8, 2018 5:42:06 GMT -5
|
|
|
Post by joeypotsandpans on Jan 8, 2018 14:20:00 GMT -5
and according to the latest from the as he states "non-conflicted" lol SO, his latest article regarding ARNA (of which he is long) he refers to Wells Fargo analyst that gives a $25/sh valuation boost for ARNA's possible treatment for PAH. www.investorvillage.com/groups.asp?mb=19370&mn=12274&pt=msg&mid=17842603the part about favorable FDA environment is akin to what Mike stated on the conference call regarding their conversations with the FDA regarding the technosphere application for Trepostinil. Where's Mike's checklist again?
|
|
|
Post by dreamboatcruise on Jan 8, 2018 16:27:04 GMT -5
joeypotsandpans... so in other words, WF is giving $1B market cap value to PAH treatment. That would be about $7 per share for MNKD at current issued share count. Even if one assumed a "worst case" amount of dilution, it alone would likely exceed the current share price of MNKD. I'm making the assumption (that I don't know would be true) here that the market potential for MNKDs trep is equivalent to what ARNA is working on.
|
|